If you have been reading about dihexa and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-21. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
The history of artificial refrigeration began when William Cullen designed a small refrigerating machine in 1755. Cullen used a pump to create a partial vacuum over a container of diethyl ether, which then boiled, absorbing heat from the surrounding air. The experiment even created a small amount of ice, but had no practical application at that time. In 1758, Benjamin Franklin and chemist John Hadley collaborated on a project investigating the principle of evaporation as a means to rapidly cool an object at Cambridge University, England. They confirmed that the evaporation of highly volatile liquids, such as alcohol and ether, could be used to drive down the temperature of an object past the freezing point of water. They conducted their experiment with the bulb of a mercury thermometer as their object and with a bellows used to quicken the evaporation; they lowered the temperature of the thermometer bulb down to −14 °C (7 °F), while the ambient temperature was 18 °C (65 °F). They noted that soon after they passed the freezing point of water 0 °C (32 °F), a thin film of ice formed on the surface of the thermometer's bulb and that the ice mass was about a 6.4 millimetres (1⁄4 in) thick when they stopped the experiment upon reaching −14 °C (7 °F). Franklin wrote, "From this experiment, one may see the possibility of freezing a man to death on a warm summer's day". In 1805, American inventor Oliver Evans described a closed vapor-compression refrigeration cycle for the production of ice by ether under vacuum.
== History == Bemethyl was developed in the 1970s by the Department of Pharmacology of the St. Petersburg State Military Medical Academy under the direction of Professor Vasily Mikhailovich Vinogradov. Professor Vinogradov and his research team earned the USSR State Prize for this accomplishment. First used with Soviet cosmonauts, bemethyl was also used to prepare athletes of the USSR national team for the Moscow 1980 Olympic Games. In the 1990s, bemethyl saw use as a basic medicinal agent in many of the corps of the Soviet and Russian armies, including Soviet troops in Afghanistan, as bemethyl facilitated increased endurance for soldiers over long marches, as well as an enhanced work capacity and stability to hypoxia and high temperatures. Bemethyl was also used to enhance the physical and mental capacities of workers deployed in the wake of the 1986 Chernobyl disaster.
==== Delta bilirubin ==== Although the terms direct and indirect bilirubin are sometimes used interchangeably with conjugated and unconjugated bilirubin, the direct fraction actually includes both conjugated bilirubin and delta bilirubin. Delta bilirubin is albumin-bound conjugated bilirubin. In the other words, delta bilirubin is the kind of bilirubin covalently bound to albumin, which appears in the serum when hepatic excretion of conjugated bilirubin is impaired in patients with hepatobiliary disease. Furthermore, direct bilirubin tends to overestimate conjugated bilirubin levels due to unconjugated bilirubin that has reacted with diazosulfanilic acid, leading to increased azobilirubin levels (and increased direct bilirubin). δ bilirubin = total bilirubin – (unconjugated bilirubin + conjugated bilirubin)
Sources: en.wikipedia.org
Furthermore, when news outlets depict mentally ill people as violent, there is a resulting increased demand by the public for "forced treatment," as exemplified in the tragedy that led to New York's establishment of Kendra's Law. In 1999, Andrew Goldstein pushed Kendra Webdale onto New York City subway tracks. The following news stories labeled Goldstein as "The Subway Psycho" and subsequently advocated for his banishment from public streets. This uprising led to the establishment of Kendra's Law, which allowed the court to order those with mental illnesses to outpatient treatment programs. The over-saturation of stories linking mental illness and violence prohibits mentally ill people from leading a normal life. Many employers are resistant to hiring those with a history of or current struggle with mental illness. Although the Equal Employment Opportunity Commission establishes guidelines to discourage hiring discrimination, the stigma persists into the workplace. Finally, the saturation of stories about violent or criminal mentally ill people overshadows the need for positive or even neutral stories. When it comes to coverage of mental illness in the news, the stories are overwhelmingly negative and tend to focus only on the dysfunction or disability aspects. Stories of recovery or accomplishment are rarely shared. This consistent framing of stories about mental illness ultimately leads to a myriad of effects.
It is an epiphytic and occasionally a lithophytic plant, forming spectacular root bundles. Its cylindric pseudobulbs can grow to a length of 2.5 m. It can grow to gigantic clusters weighing from several hundred kilograms to more than one tonne. One collected in 1893 by Frederick K. Sander & Co. near Penang Island in Malaysia weighed 1 t (0.98 long tons; 1.1 short tons). Half was sent to the Columbian Exhibition in Chicago and the other half to the Singapore Botanic Garden. By 1902, the Singapore specimen had grown to be 14.4 m (47 ft) girth by 3 m (9.8 ft) high, and bore simultaneously 2,090 12.5 cm (4.9 in) wide gold and mahogany-coloured flowers plus 1110 unopened buds. Much more recently, in A.D. 2000, biologists Tim Laman and Phil Atkinson found one in Borneo 7.7 m (25 ft) wide and bearing between 2500 and 5000 flowers. The plant completely encircled the host tree 46 m (151 ft) above the ground. The oldest known individual orchid plant is also a G. speciosum. Planted in the Singapore Botanic Garden in 1861 by Garden Director Lawrence Niven and his staff, it was 154 years old in 2015. The plant is also 5 m (16 ft) in width. Each raceme can grow to a height of 3 m, bearing up to 80 flowers, each 10 cm wide. The flowers are yellow with maroon or dark red spots. These flowers are unusual, since the lowest flowers have no lip and these flowers function as osmophores for the entire inflorescence and continue to emit chemical scent to attract pollinators as flowers open in succession. It blooms only once every two to four years.
=== Deformed nuclei === Though nuclei within the island of stability around N = 184 are predicted to be spherical, studies from the early 1990s—beginning with Polish physicists Zygmunt Patyk and Adam Sobiczewski in 1991—suggest that some superheavy elements do not have perfectly spherical nuclei. A change in the shape of the nucleus changes the position of neutrons and protons in the shell. Research indicates that large nuclei farther from spherical magic numbers are deformed, causing magic numbers to shift or new magic numbers to appear. Current theoretical investigation indicates that in the region Z = 106–108 and N ≈ 160–164, nuclei may be more resistant to fission as a consequence of shell effects for deformed nuclei; thus, such superheavy nuclei would only undergo alpha decay. Hassium-270 is now believed to be a doubly magic deformed nucleus, with deformed magic numbers Z = 108 and N = 162. It has a half-life of 9 seconds. This is consistent with models that take into account the deformed nature of nuclei intermediate between the actinides and island of stability near N = 184, in which a stability "peninsula" emerges at deformed magic numbers Z = 108 and N = 162. Determination of the decay properties of neighboring hassium and seaborgium isotopes near N = 162 provides further strong evidence for this region of relative stability in deformed nuclei.
Sources: en.wikipedia.org
UK academic and end-user community funded by UKRI: UK Metamaterials Network UK Government Rapid Technology Assessment looking at Metamaterials PwC Tech Translated: Metamaterials Centre for Metamaterial Research and Innovation, University of Exeter, UK www.metamaterials.center Institute of Physics, Impact Project Pathway "Commercialising Metamaterials"
=== 6 March === Sudan filed a case in the International Court of Justice (ICJ) against the United Arab Emirates, accusing it of complicity in genocide by providing weapons to the RSF. Canada imposed sanctions on al-Burhan and Hemedti, citing in part "an unwillingness on the part of the leaders to negotiate an end to the war".
Good Clinical Practice Committee Good Laboratory Practice Committee Good Manufacturing Practice Committee Good Pharmacovigilance Practice Committee Animal and Veterinary Product Committee D.I.G.I.T. Committee Medical Devices Committee
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.